AKT1 and myelodysplastic syndrome: Although MK2206 effectively suppresses AKT phosphorylation, it has not been successful in monotherapy (similar to PI3Ki), but its good tolerability opens the possibility of its inclusion in combination strategies for AZA-R MDS.